Pharmacotherapy for pulmonary arterial hypertension

被引：47

作者：

Parikh, Vishal ^{[1
]}

Bhardwaj, Anju ^{[2
]}

Nair, Ajith ^{[3
]}

机构：

[1] Baylor Coll Med, Texas Heart Inst, Houston, TX 77030 USA

[2] McGovern Med Sch, Ctr Adv Cardiopulm Therapies & Transplantat, Houston, TX USA

[3] Baylor Coll Med, Texas Heart Inst, Winters Ctr Heart Failure Res, Michael E DeBakey VA Med Ctr,Educ Fac, Houston, TX 77030 USA

来源：

JOURNAL OF THORACIC DISEASE | 2019年 / 11卷

关键词：

Pulmonary arterial hypertension (PAH); nitric oxide; endothelin; prostacyclin; sildenafil; tadalafil; riociguat; bosentan; ambrisentan; macitentan; epoprostenol; treprostinil; selexipag; CONTINUOUS INTRAVENOUS EPOPROSTENOL; ENDOTHELIN RECEPTOR ANTAGONIST; 5 INHIBITOR THERAPY; DOUBLE-BLIND; ORAL TREPROSTINIL; EISENMENGER-SYNDROME; BOSENTAN THERAPY; PROSTACYCLIN; SITAXSENTAN; MULTICENTER;

D O I：

10.21037/jtd.2019.09.14

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Pulmonary arterial hypertension (PAH) is a condition associated with substantial morbidity and mortality. Over the last 25 years there has been a significant evolution in the therapies to treat PAH. These therapies are effective for patients with group I PAH and group IV PH [chronic thromboembolic pulmonary hypertension (CTEPH)]. PAH is characterized by an imbalance of nitric oxide, prostacyclin and endothelin levels, and current pharmacotherapy involves these three pathways. Earlier clinical trials involving PAH-specific therapies evaluated improvements in 6-minute walk time as a primary improvement whereas contemporary trials have been larger and focused on morbidity and mortality reductions. While there may be a role for monotherapy in disease management, most patients should be considered for dual or triple therapy.

引用

页码：S1767 / S1781

页数：15

共 46 条

[1] Riociguat for Pulmonary Hypertension A Glass Half Full [J].

Archer, Stephen L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (04) :386-388

[2] Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension. [J].

Archer, Stephen L. ;

Michelakis, Evangelos D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (19) :1864-1871

[3] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].

Badesch, DB ;

Tapson, VF ;

McGoon, MD ;

Brundage, BH ;

Rubin, LJ ;

Wigley, FM ;

Rich, S ;

Barst, RJ ;

Barrett, PS ;

Kral, KM ;

Jöbsis, MM ;

Loyd, JE ;

Murali, S ;

Frost, A ;

Girgis, R ;

Bourge, RC ;

Ralph, DD ;

Elliott, CG ;

Hill, NS ;

Langleben, D ;

Schilz, RJ ;

McLaughlin, VV ;

Robbins, IM ;

Groves, BM ;

Shapiro, S ;

Medsger, TA ;

Gaine, SP ;

Horn, E ;

Decker, JC ;

Knobil, K .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+

[4] Sitaxsentan therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

Langleben, D ;

Frost, A ;

Horn, EM ;

Oudiz, R ;

Shapiro, S ;

McLaughlin, V ;

Hill, N ;

Tapson, VF ;

Robbins, IM ;

Zwicke, D ;

Duncan, B ;

Dixon, RAF ;

Frumkin, LR .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447

[5] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[6] Beraprost therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

McGoon, M ;

McLaughlin, V ;

Tapson, V ;

Oudiz, R ;

Shapiro, S ;

Robbins, IM ;

Channick, R ;

Badesch, D ;

Rayburn, BK ;

Flinchbaugh, R ;

Sigman, J ;

Arneson, C ;

Jeffs, R .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) :2119-2125

[7] Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension A 1-Year, Prospective, Open-Label Observation of Outcome and Survival [J].

Benza, Raymond L. ;

Barst, Robyn J. ;

Galie, Nazzareno ;

Frost, Adaani ;

Girgis, Reda E. ;

Highland, Kristin B. ;

Strange, Charlie ;

Black, Carol M. ;

Badesch, David B. ;

Rubin, Lewis ;

Fleming, Thomas R. ;

Naeije, Robert .

CHEST, 2008, 134 (04) :775-782

[8] Diagnosis of pulmonary hypertension [J].

Frost, Adaani ;

Badesch, David ;

Gibbs, J. Simon R. ;

Gopalan, Deepa ;

Khanna, Dinesh ;

Manes, Alessandra ;

Oudiz, Ronald ;

Satoh, Toru ;

Torres, Fernando ;

Torbicki, Adam .

EUROPEAN RESPIRATORY JOURNAL, 2019, 53 (01)

[9] Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study):: a double-blind, randomised controlled trial [J].

Galie, N. ;

Rubin, L. J. ;

Hoeper, M. M. ;

Jansa, P. ;

Al-Hiti, H. ;

Meyer, G. M. B. ;

Chiossi, E. ;

Kusic-Pajic, A. ;

Simonneau, G. .

LANCET, 2008, 371 (9630) :2093-2100

[10] Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension [J].

Galie, N. ;

Barbera, J. A. ;

Frost, A. E. ;

Ghofrani, H-A. ;

Hoeper, M. M. ;

McLaughlin, V. V. ;

Peacock, A. J. ;

Simonneau, G. ;

Vachiery, J-L. ;

Gruenig, E. ;

Oudiz, R. J. ;

Vonk-Noordegraaf, A. ;

White, R. J. ;

Blair, C. ;

Gillies, H. ;

Miller, K. L. ;

Harris, J. H. N. ;

Langley, J. ;

Rubin, L. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (09) :834-844

← 1 2 3 4 5 →